Alejandro Bustamante1, Elena López-Cancio1, Sara Pich1, Anna Penalba1, Dolors Giralt1, Teresa García-Berrocoso1, Carles Ferrer-Costa1, Teresa Gasull1, María Hernández-Pérez1, Mónica Millan1, Marta Rubiera1, Pedro Cardona1, Luis Cano1, Helena Quesada1, Mikel Terceño1, Yolanda Silva1, Mar Castellanos1, Moisés Garces1, Silvia Reverté1, Xavier Ustrell1, Rafael Marés1, Joan Josep Baiges1, Joaquín Serena1, Francisco Rubio1, Eduardo Salas1, Antoni Dávalos1, Joan Montaner2. 1. From the Neurovascular Research Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain (A.B., A.P., D.G., T.G.-B., J.M.); Stroke Unit, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain (E.L.-C., M.H.-P., M.M., A.D.); Gendiag.exe, S.L., Barcelona, Spain (S.P., C.F.-C., E.S.); Cellular and Molecular Neurobiology Research Group, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain (T.G.); Stroke Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain (M.R., J.M.); Stroke Unit, Hospital Universitari de Bellvitge, Barcelona, Spain (P.C., L.C., H.Q., F.R.); Stroke Unit, Hospital Universitari Josep Trueta, Girona, Spain (M.T., Y.S., J.S.); Complejo Hospitalario Universitario A Coruña, Spain (M.C.); Stroke Unit, Hospital Universitari Verge de la Cinta de Tortosa, Spain (M.G., S.R., J.J.B.); and Stroke Unit, Hospital Universitari Joan XXIII, Tarragona, Spain (X.U., R.M.). 2. From the Neurovascular Research Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain (A.B., A.P., D.G., T.G.-B., J.M.); Stroke Unit, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain (E.L.-C., M.H.-P., M.M., A.D.); Gendiag.exe, S.L., Barcelona, Spain (S.P., C.F.-C., E.S.); Cellular and Molecular Neurobiology Research Group, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain (T.G.); Stroke Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain (M.R., J.M.); Stroke Unit, Hospital Universitari de Bellvitge, Barcelona, Spain (P.C., L.C., H.Q., F.R.); Stroke Unit, Hospital Universitari Josep Trueta, Girona, Spain (M.T., Y.S., J.S.); Complejo Hospitalario Universitario A Coruña, Spain (M.C.); Stroke Unit, Hospital Universitari Verge de la Cinta de Tortosa, Spain (M.G., S.R., J.J.B.); and Stroke Unit, Hospital Universitari Joan XXIII, Tarragona, Spain (X.U., R.M.). joan.montaner@vhir.org.
Abstract
BACKGROUND AND PURPOSE: Stroke diagnosis could be challenging in the acute phase. We aimed to develop a blood-based diagnostic tool to differentiate between real strokes and stroke mimics and between ischemic and hemorrhagic strokes in the hyperacute phase. METHODS: The Stroke-Chip was a prospective, observational, multicenter study, conducted at 6 Stroke Centers in Catalonia. Consecutive patients with suspected stroke were enrolled within the first 6 hours after symptom onset, and blood samples were drawn immediately after admission. A 21-biomarker panel selected among previous results and from the literature was measured by immunoassays. Outcomes were differentiation between real strokes and stroke mimics and between ischemic and hemorrhagic strokes. Predictive models were developed by combining biomarkers and clinical variables in logistic regression models. Accuracy was evaluated with receiver operating characteristic curves. RESULTS: From August 2012 to December 2013, 1308 patients were included (71.9% ischemic, 14.8% stroke mimics, and 13.3% hemorrhagic). For stroke versus stroke mimics comparison, no biomarker resulted included in the logistic regression model, but it was only integrated by clinical variables, with a predictive accuracy of 80.8%. For ischemic versus hemorrhagic strokes comparison, NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) >4.9 (odds ratio, 2.40; 95% confidence interval, 1.55-3.71; P<0.0001) and endostatin >4.7 (odds ratio, 2.02; 95% confidence interval, 1.19-3.45; P=0.010), together with age, sex, blood pressure, stroke severity, atrial fibrillation, and hypertension, were included in the model. Predictive accuracy was 80.6%. CONCLUSIONS: The studied biomarkers were not sufficient for an accurate differential diagnosis of stroke in the hyperacute setting. Additional discovery of new biomarkers and improvement on laboratory techniques seem necessary for achieving a molecular diagnosis of stroke.
BACKGROUND AND PURPOSE:Stroke diagnosis could be challenging in the acute phase. We aimed to develop a blood-based diagnostic tool to differentiate between real strokes and stroke mimics and between ischemic and hemorrhagic strokes in the hyperacute phase. METHODS: The Stroke-Chip was a prospective, observational, multicenter study, conducted at 6 Stroke Centers in Catalonia. Consecutive patients with suspected stroke were enrolled within the first 6 hours after symptom onset, and blood samples were drawn immediately after admission. A 21-biomarker panel selected among previous results and from the literature was measured by immunoassays. Outcomes were differentiation between real strokes and stroke mimics and between ischemic and hemorrhagic strokes. Predictive models were developed by combining biomarkers and clinical variables in logistic regression models. Accuracy was evaluated with receiver operating characteristic curves. RESULTS: From August 2012 to December 2013, 1308 patients were included (71.9% ischemic, 14.8% stroke mimics, and 13.3% hemorrhagic). For stroke versus stroke mimics comparison, no biomarker resulted included in the logistic regression model, but it was only integrated by clinical variables, with a predictive accuracy of 80.8%. For ischemic versus hemorrhagic strokes comparison, NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) >4.9 (odds ratio, 2.40; 95% confidence interval, 1.55-3.71; P<0.0001) and endostatin >4.7 (odds ratio, 2.02; 95% confidence interval, 1.19-3.45; P=0.010), together with age, sex, blood pressure, stroke severity, atrial fibrillation, and hypertension, were included in the model. Predictive accuracy was 80.6%. CONCLUSIONS: The studied biomarkers were not sufficient for an accurate differential diagnosis of stroke in the hyperacute setting. Additional discovery of new biomarkers and improvement on laboratory techniques seem necessary for achieving a molecular diagnosis of stroke.
Authors: Elizabeth Parody-Rua; Alejandro Bustamante; Joan Montaner; Maria Rubio-Valera; David Serrano; Soledad Pérez-Sánchez; Alba Sánchez-Viñas; César Guevara-Cuellar; Antoni Serrano-Blanco Journal: Eur J Health Econ Date: 2022-07-27
Authors: Grant C O'Connell; Megan L Alder; Christine G Smothers; Julia H C Chang Journal: Proc Natl Acad Sci U S A Date: 2020-08-06 Impact factor: 11.205
Authors: Daniela Frizon Alfieri; Marcio Francisco Lehmann; Tamires Flauzino; Maria Caroline Martins de Araújo; Nicolas Pivoto; Rafaele Maria Tirolla; Andrea Name Colado Simão; Michael Maes; Edna Maria Vissoci Reiche Journal: Neurotox Res Date: 2020-05-15 Impact factor: 3.911
Authors: Lisa Shaw; Sara Graziadio; Clare Lendrem; Nicholas Dale; Gary A Ford; Christine Roffe; Craig J Smith; Philip M White; Christopher I Price Journal: Diagn Progn Res Date: 2021-05-20